Catalog No.
Product Name
Application
Product Information
Citations
-
NF-κB Inhibitor
Teuclatriol is an NF-κB inhibitor derived from Salvia mirzayanii, exhibiting notable anti-inflammatory properties. It effectively inhibits TNF-α secretion in a dose-dependent manner, making it valuable for research involving inflammatory pathways and the modulation of NF-κB activity. This compound is essential for studies focused on chronic inflammation, autoimmune diseases, and related therapeutic developments. -
NF-κB Inhibitor
NF-κB-IN-13 is a selective inhibitor of the NF-κB signaling pathway. This compound effectively suppresses lipopolysaccharide (LPS)-induced NF-κB activation and nitric oxide (NO) production in RAW264.7 macrophages, demonstrating its potential anti-inflammatory properties. NF-κB-IN-13 is valuable for research applications focusing on inflammation, immune response modulation, and potential therapeutic strategies for related diseases. -
NF-κB Inhibitor
APC0576 is an NF-κB inhibitor that effectively disrupts the activation of the NF-κB signaling pathway, demonstrating an IC50 of 1.0 μM for β-galactosidase. This compound significantly inhibits the release of IL-1-induced chemokines, making it a valuable tool for research related to diseases involving pathological endothelial cell activation. Its targeted action allows for the exploration of therapeutic strategies aimed at modulating inflammatory responses. -
NF-κB Inhibitor
CAY10657 is a potent NF-κB inhibitor that effectively downregulates the expression of proinflammatory cytokines, including IL-6, and chemokines such as MCP-1. This compound demonstrates significant anti-inflammatory activity, particularly in the context of meningitis induced by Streptococcus suis. CAY10657 is a valuable tool for researchers investigating inflammation and associated signaling pathways. -
NF-κB Inhibitor
Icariside F2 is a selective NF-κB inhibitor with an IC50 value of 16.25 μM. This aromatic glycoside, extracted from the leaves of E. ulmoides Oliver, exhibits significant anti-inflammatory activity. It is utilized in biomedical research to explore therapeutic strategies for conditions mediated by NF-κB signaling. -
Stable Isotope
TML-6-d3 is a deuterated derivative of the curcumin compound TML-6, demonstrating stability as a labeled isotope. This reagent primarily inhibits the synthesis of β-amyloid precursor protein and β-amyloid (Aβ), contributing to research in neurodegenerative diseases. TML-6-d3 upregulates ApoE, suppresses NF-κB and mTOR signaling pathways, and enhances activities related to neuroprotection. It serves as a valuable tool for studying the molecular mechanisms of Alzheimer's disease and related disorders. -
ROR-γ Inhibitor
CID 7309015 is a selective inhibitor of retinoic acid-related orphan receptor gamma (ROR-γ). This compound demonstrates significant potential in modulating inflammatory pathways, particularly in the context of NF-κB signaling and inflammatory arthritis research. CID 7309015 serves as a valuable tool for investigating the roles of ROR-γ in immune response and inflammatory diseases. -
Sigma-2 ligand/Agonist
SW43 is a selective Sigma-2 ligand and agonist that plays a pivotal role in cancer research. This compound enhances the development of targeted therapeutic agents, showing significant antitumor activity when conjugated with DOX-L-NETA (89Y) in a VX2 liver tumor allograft rabbit model. Additionally, when combined with SW IV-52s to create SW III-123, SW43 activates the NF-κB pathway, demonstrating potent cytotoxic effects against ovarian cancer cell lines and promoting apoptosis. This dual functionality underscores its utility in cancer therapeutic development. -
TBK1/IKKε Inhibitor
BAY-985 is a selective ATP-competitive dual inhibitor targeting TBK1 and IKKε, demonstrating high potency with IC50 values of 2 nM for TBK1 under low ATP conditions and 30 nM under high ATP conditions, and 2 nM for IKKε. This inhibitor exhibits significant antitumor activity, making it a valuable tool for research applications focused on cancer therapy and the modulation of inflammatory pathways. Its oral bioavailability further enhances its utility in preclinical studies. -
IKKα Inhibitor
BAY32-5915 is a selective inhibitor of IKKα, exhibiting an IC50 value of 60 nM. This compound effectively prevents the activation of NF-κB without interfering with Doxorubicin-induced pathways. It is valuable for research in inflammation and cancer, providing insights into NF-κB signaling modulation. -
IKK/NF-κB Inhibitor
NF-κB-IN-1 is a selective inhibitor of the IκB kinase (IKK) and functions primarily through the inhibition of NF-κB signaling. This compound effectively blocks the activation of NF-κB, demonstrating potent anti-cancer activity by reducing cell viability in lung cancer cells. Additionally, NF-κB-IN-1 significantly diminishes the clonogenic potential of A549 cells, making it a valuable tool for research on cancer therapeutics targeting NF-κB pathways. -
Negative control of IKK
6-Chloro-7-deazaguanine serves as a negative control for IκB kinase (IKK), specifically lacking the essential 5-cyano group that defines its activity. As an inactive analog, it provides a useful reference for studying the IKKβ and IKKα pathways, which are crucial components of the canonical and non-canonical NF-κB signaling pathways. Researchers can utilize this compound to delineate the role of IKK in various cellular processes and disease models, particularly in inflammation and immune responses. -
IKK Inhibitor
SU1261 is a potent inhibitor of IKK, displaying Ki values of 10 nM for IKKα and 680 nM for IKKβ. This compound effectively inhibits non-canonical NF-κB signaling pathways, making it a valuable tool for studying the role of IKK in various cellular processes. Its application in research, particularly in osteosarcoma cell models such as U2OS, can provide insights into inflammatory responses and oncogenic signaling mechanisms. -
IKK/NF-κB Inhibitor
SR12343 is an IKK/NF-κB inhibitor that acts as a mimetic of the NF-κB essential modulator (NEMO)-binding domain. It effectively disrupts the interaction between IKKβ and NEMO, leading to inhibition of TNF-α- and LPS-induced NF-κB activation, with an IC50 of 37.02 μM for TNF-α-mediated pathways. SR12343 has been shown to reduce LPS-induced acute pulmonary inflammation in murine models, making it valuable for research into inflammatory and degenerative diseases. -
TBK1/IKKε Inhibitor
TBK1/IKKε-IN-4 is a selective inhibitor of TBK1 and IKKε, characterized by its 6-aminopyrazolopyrimidine structure. With IC50 values of 13 nM and 59 nM for TBK1 and IKKε, respectively, this compound demonstrates significant potency. It exhibits minimal activity against other protein kinases, including PDK1, PI3K family members, and mTOR, making it an efficient tool for investigating TBK1/IKKε-related pathways in various biological contexts. This inhibitor is useful for studies in inflammation, immune response, and neurodegenerative diseases. -
IKKβ Inhibitor
BOT-64 is a selective IκB kinase β (IKKβ) inhibitor with an IC50 value of 1 µM. This compound effectively inhibits lipopolysaccharide-induced activation of nuclear factor-κB (NF-κB) and the subsequent transcription of NF-κB-regulated inflammatory genes. BOT-64 is valuable for research into inflammatory pathways and NF-κB signaling, providing insights into potential therapeutic strategies for inflammatory diseases. -
IKK-2 Inhibitor
IKK2-IN-4 is a selective inhibitor of IKK-2, exhibiting a potent IC50 value of 25 nM. This compound effectively inhibits LPS-induced TNFα production in peripheral blood mononuclear cells (PBMCs), making it a valuable tool for studying inflammatory responses. Research applications include investigations into signaling pathways involved in inflammation and potential therapeutic strategies for immune-related disorders. -
IKK Inhibitor
HPN-01 is a potent and selective inhibitor of IκB kinase (IKK), demonstrating pIC50 values of 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε, respectively. This compound exhibits significant selectivity, showing more than 50-fold preference over a diverse panel of over 50 kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2. HPN-01 is a valuable tool for research applications focused on inflammatory pathways, cancer cell signaling, and the study of immune responses. -
ikkβ Inhibitor
IKKβ-IN-4 is a selective inhibitor of IkappaB kinase-β (IKKβ), with an IC50 value of 1.9 μM. IKKβ plays a crucial role in the NF-κB signaling pathway, which is implicated in various diseases, including inflammation and cancer. This compound is utilized in research to study the modulation of NF-κB activity and its potential therapeutic applications in related disease models. -
IKKβ Inhibitor
MLN120B dihydrochloride is a potent inhibitor of IKKβ, exhibiting competitive ATP binding with an IC50 of 60 nM. This compound effectively inhibits the growth of multiple myeloma cells both in vitro and in vivo, making it a valuable tool for cancer research. Additionally, MLN120B can be utilized in studies focused on rheumatoid arthritis, contributing to the understanding of inflammatory pathways and potential therapeutic interventions. -
IKK2 Inhibitor
IKK2-IN-3 is a selective inhibitor of IKK2, demonstrating a potent inhibitory effect with an IC50 value of 0.075 μM. This compound effectively disrupts the NF-κB signaling pathway, impacting various cellular processes such as inflammation and immune response. IKK2-IN-3 is suitable for research applications involving the modulation of IKK2 activity in disease models and studying the role of NF-κB in cellular signaling. -
IKK2 Inhibitor
LY2409881 is a selective inhibitor of IκB kinase β (IKK2), demonstrating potent inhibition with an IC50 of 30 nM. This compound is primarily used in research for its ability to modulate the NF-κB signaling pathway, making it relevant for studying inflammation, cancer, and autoimmune diseases. Researchers utilize LY2409881 to explore its therapeutic potential in various disease models and to investigate the role of IKK2 in cellular processes. -
IκB Kinase-2 Inhibitor
PS-1145 dihydrochloride is a selective inhibitor of IκB kinase-2, exhibiting an IC50 value of 88 nM. This compound effectively inhibits the phosphorylation of IκB kinase, thereby suppressing NF-κB activity. PS-1145 dihydrochloride is utilized in research applications targeting inflammatory responses and cancer biology. -
IKK2 Inhibitor
IKK-IN-4 is a selective inhibitor of IkappaB kinase 2 (IKKβ), exhibiting an IC50 of 45 nM for IKKβ and 650 nM for IKKα. This compound is instrumental in research focusing on the NF-κB signaling pathway and its regulation, providing insights into inflammation, cancer, and other diseases linked to IKK activity. IKK-IN-4 serves as a valuable tool for studying IKKβ-mediated signaling mechanisms and potential therapeutic interventions. -
TBK1/IKKi Dual Inhibitor
SR8185 is a potent dual inhibitor of TBK1 and IKKi, exhibiting IC50 values of 3 nM and less than 10 nM, respectively. This compound demonstrates significant antiproliferative effects across a wide range of human cancer cell lines. SR8185 is ideal for exploring cancer-related pathways and therapeutic strategies in cancer research. -
IKKβ Inhibitor
IKKβ-IN-1 is a selective inhibitor of IkappaB kinase beta (IKK-β), exhibiting an IC50 of 0.20 μM. This compound effectively reduces the production of pro-inflammatory cytokines such as PGE2 and TNF-α in mouse macrophage cells. Additionally, IKKβ-IN-1 has demonstrated protective effects against mortality in mice subjected to septic shock, highlighting its potential for research in inflammation and immune response. -
TBK1 and IKKε Inhibitor
TBK1/IKKε-IN-6 is a selective inhibitor of TBK1 and IKKε, exhibiting IC50 values below 100 nM for both targets. This compound plays a significant role in modulating inflammatory signaling pathways by inhibiting the activation of these kinases. It is particularly useful in research focused on autoimmune diseases, cancer, and viral infections, enabling the exploration of therapeutic strategies targeting the TBK1/IKKε pathway. -
IKK Inhibitor
(E/Z)-HOIPIN-1 is a selective inhibitor of the linear ubiquitin chain assembly complex (LUBAC), targeting the IκB kinase (IKK) pathway. With an IC50 value greater than 2.8 μM, this compound effectively inhibits LUBAC-mediated NF-κB activation. Its potential applications include studies of inflammatory responses, cancer biology, and the modulation of immune signaling pathways. -
IKK-β Inhibitor
SAR113945 is a highly potent inhibitor of IKK-β, exhibiting an IC50 value of 0.4 nM. This compound is primarily utilized in research focusing on inflammatory pathways and oncogenic processes. Its efficacy makes it a valuable tool for investigating the role of IKK-β in various disease states, particularly in understanding mechanisms underlying inflammation and cancer progression. -
IKKβ Inhibitor
MLN-0415 is an inhibitor of IKKβ, a key regulator in the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory activity and is instrumental in researching conditions such as arthritis and other inflammatory diseases. MLN-0415 facilitates the exploration of therapeutic strategies targeting the modulation of inflammatory responses. -
IKK-2 Inhibitor
(Rac)-PF-184 is a selective inhibitor of the inhibitor of κB kinase 2 (IKK-2) with an IC50 value of 37 nM. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammatory signaling pathways. It is suitable for studies investigating the role of IKK-2 in various biological processes and disease models. -
IKKβ Inhibitor
1-Dehydro-[10]-gingerdione functions as a selective inhibitor of IKKβ by targeting its activation loop, leading to the disruption of IKKβ-mediated phosphorylation of IκBα in macrophages stimulated with various agonists. This compound effectively inhibits LPS-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione holds promise for research into NF-κB-related inflammation and autoimmune disorders. -
Vasodilator
(Z)-11,12-Epoxyeicosatrienoic acid acts as a potent vasodilator, primarily targeting small renal arteries. This compound exhibits anti-inflammatory properties by inhibiting leukocyte adhesion to the vascular wall through modulation of the NF-κB signaling pathway and IκB kinase (IKK) activity. It is suitable for research applications focused on vascular inflammation and related cardiovascular studies. -
IKK2 Inhibitor
IKK-IN-3 is a potent and selective inhibitor of IkappaB kinase 2 (IKK2, also known as IKKβ), exhibiting IC50 values of 19 nM for IKK2 and 400 nM for IKK1 (IKKα). This compound is valuable in research focused on the regulation of the NF-kB signaling pathway, which plays a critical role in inflammation, immune responses, and cancer progression. IKK-IN-3 can be utilized to investigate the therapeutic potential of IKK2 inhibition in various disease models. -
IkappaB kinase inhibitor
CGA-JK3 is an ATP-competitive inhibitor of IκB kinase (IKKβ), effectively hindering its kinase activity. This compound inhibits the phosphorylation of IκBα in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, demonstrating its potential in studying inflammatory signaling pathways. CGA-JK3 is useful for researchers investigating the modulation of NF-κB signaling and related biological processes. -
IKKα/β Inhibitor
GTCpFE is a selective inhibitor of IKKα/β, functioning within the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory properties by preventing the nuclear translocation of the p65 subunit of NF-κB. Additionally, GTCpFE demonstrates targeted anti-cancer stem-like cell activity by impairing mammosphere formation and reducing the CD44+ CD24- immunophenotype associated with aggressive breast cancer. Its dual mechanism positions GTCpFE as a promising agent for both inflammation and cancer research. -
IKK Inhibitor
TBK1/IKKε-IN-1 is a potent dual inhibitor of TBK1 and IKKε, demonstrating IC50 values of less than 100 nM. This compound is valuable for research applications involving the modulation of inflammatory pathways and immune responses. Its inhibition of these kinases provides a tool for studying their roles in various biological processes and disease states, particularly those related to cancer and neuroinflammation. -
PI3K/PIKK Inhibitor
PI3K/PIKK-IN-2 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) and phosphoinositide-dependent kinase (PIKK) pathways. This compound demonstrates significant biological activity by modulating signaling pathways involved in cell growth, metabolism, and survival. PI3K/PIKK-IN-2 is suitable for use in research applications focused on targeted therapies, including the development of antibody-drug conjugates (ADCs). -
Stable Isotope
Ceramide 3-d3 (N-Stearoyl phytosphingosine-d3) is a deuterated form of Ceramide 3, a bioactive sphingolipid notably present in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. With a phytosphingosine backbone linked to a C18 fatty acid chain, Ceramide 3-d3 plays a crucial role in regulating apoptosis and cell differentiation, while also supporting smooth muscle cell proliferation and inhibiting the mitochondrial respiratory chain. Furthermore, it suppresses the expression of pro-inflammatory cytokines IL-4 and TNF-α, as well as transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue, making it valuable for research in skin health and inflammation. -
Ophthalmic Preservative
Polyquaternium-1 (Polidronium chloride; PQ-1) is an effective ophthalmic preservative with antimicrobial properties, which activates the NF-κB signaling pathway. It acts by targeting bacterial cell membranes, utilizing its polycationic nature to disrupt membrane integrity, inducing potassium ion leakage, and resulting in bacterial cell death. At a concentration of 0.001%, Polyquaternium-1 exhibits low toxicity towards mammalian cells, making it suitable for various formulations including glaucoma eye drops, artificial tears, and contact lens solutions. Its use helps to mitigate the ocular surface toxicity associated with conventional preservatives like benzalkonium chloride. -
Biochemical Assay Reagent
Ceramide 3, a bioactive sphingolipid, plays a crucial role in cellular processes by regulating apoptosis, cell differentiation, and the proliferation of smooth muscle cells. This compound functions by inhibiting the mitochondrial respiratory chain and suppressing the expression of allergic cytokines such as IL-4 and TNF-α, as well as transcription factors like c-Jun and NF-κB in histone-stimulated mouse skin tissue. Ceramide 3 is utilized in various biochemical assays and has applications in dermatological research, particularly in studies related to skin barrier function and hydration. -
Stable Isotope
17-Epiestriol-d5-1 is a deuterated form of 17-Epiestriol, a selective estrogen receptor (ER) β agonist. This compound functions as an effective inhibitor of vascular cell adhesion molecule VCAM-1 expression induced by tumor necrosis factor α (TNFα) and prevents the nuclear translocation of NF-κB. Additionally, 17-Epiestriol-d5-1 promotes the expression of endothelial nitric oxide synthase at both mRNA and protein levels. It serves as a valuable tool in research exploring estrogen receptor signaling and its implications in cardiovascular and inflammatory responses. -
Estrogen Receptor Agonist
Dehydrodiconiferyl alcohol is an estrogen receptor agonist that plays a significant role in promoting BMP-2-induced osteoblastogenesis. Additionally, this compound exhibits anti-inflammatory properties by inactivating NF-κB pathways. It is relevant for research in bone metabolism and inflammatory response modulation. -
ER Agonist
17-Epiestriol is an estrogen metabolite that acts as a selective estrogen receptor (ER) β agonist. It is known to inhibit the mRNA and protein expression of vascular cell adhesion molecule VCAM-1 induced by tumor necrosis factor α (TNFα), thereby preventing NF-κB migration to the nucleus. Additionally, 17-epiestriol promotes the expression of endothelial nitric oxide synthase at both mRNA and protein levels. This compound is useful in research related to vascular inflammation and endothelial function. -
HDAC8 Modulator
LG190119 is a selective modulator of HDAC8, primarily targeting Schistosoma mansoni with reduced affinity for human HDAC8. This compound has been shown to induce apoptosis in schistosome cells, making it a valuable tool for research in anti-parasitic agents. Its ability to selectively affect parasitic cells underscores its potential in developing effective treatments against schistosomiasis. -
HDAC inhibitor
Resminostat, also known as RAS2410, is a potent inhibitor of histone deacetylase (HDAC) classes I and II. It binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. -
IKK2/IKK1 inhibitor
BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM
